Insider Trading Alert - IRWD, GMED, DST, RRC And GTN Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Jan. 16, 2014, 73 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $35.09 to $29,478,000.00.

Highlighted Stocks Traded by Insiders:

Ironwood Pharmaceuticals (IRWD) - FREE Research Report

Roberts Bryan E who is Director at Ironwood Pharmaceuticals sold 21,200 shares at $12.57 on Jan. 16, 2014. Following this transaction, the Director owned 143,617 shares meaning that the stake was reduced by 12.86% with the 21,200-share transaction.

The shares most recently traded at $12.25, down $0.32, or 2.61% since the insider transaction.

The average volume for Ironwood Pharmaceuticals has been 996,600 shares per day over the past 30 days. Ironwood Pharmaceuticals has a market cap of $1.2 billion and is part of the health care sector and health services industry. Shares are up 5.51% year-to-date as of the close of trading on Thursday.

Ironwood Pharmaceuticals, Inc., an entrepreneurial pharmaceutical company, discovers, develops, and commercializes human therapeutic products. Currently there are 5 analysts that rate Ironwood Pharmaceuticals a buy, 1 analyst rates it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IRWD - FREE

TheStreet Quant Ratings rates Ironwood Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally high debt management risk. Get the full Ironwood Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Ironwood Shares Jump on FDA Approval for Hyperuricemia Drug - Biotech Movers

5 Ways Allergan Can Keep Up Momentum

Premarket Biotech Movers: Ironwood Pharmaceuticals, Rigel Pharmaceuticals, FibroGen

Synergy Pharmaceuticals Secures Approval for Linzess Competitor

Ironwood Pharmaceuticals (IRWD): Today's Weak On High Volume Stock